Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination of Nivolumab and Ipilimumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
NCT02530463Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2015
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in myelodysplastic syndrome (MDS) (6 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate at 24 weeks. Started Sep 2015; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02530463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530463.